“Our woolly mouse project drove innovations in areas combining the end to end process from our computational biology analysis tools to our multiplex precision genome engineering technologies,” Lamm told us. “These technologies enable precise and efficient genetic modifications at multiple sites within the genome at the same time, which could help with research focused on addressing the complex multi-genetic age-related diseases in the future.”

By further refining the genetic engineering techniques developed by Colossal, researchers may eventually develop therapies tailored to an individual’s genetic makeup, mitigating the effects of aging at a cellular level.

“Many diseases are multigenic in nature and require deep analysis computationally and being able to edit the genome at multiple sites with high degrees of efficiency to not cause off-target effects,” Lamm told us. “Our end to end process and the further development of our multiplex editing and DNA synthesis capabilities will lead to others being able to use our tools and system to treat these more complicated diseases. Together, these innovations are part of the science focused on developing personalized, targeted therapies to mitigate the effects of aging, accelerate the development of regenerative medicine, and extend both lifespan and healthspan.”